Considerations for Tapering Benzodiazepine in Primary Care

Product not yet rated

Includes a Live Web Event on 05/19/2025 at 12:00 PM (EDT)

  • Register
    • Non-Member - Free!
    • Regular Member - Free!
    • Retired - Free!
    • Early Career Physician - Free!
    • Resident - Free!
    • Student - Free!
    • Associate - Free!
    • ASAM Staff - Free!
    • International Member - Free!
    • Emeritus Member - Free!
    • Provisional Member - Free!
    • Fellow Member - Free!
    • Honorary Member - Free!
    • CRT Member - Free!

Considerations for Tapering Benzodiazepines in Primary Care

Monday, May 19, 2025

12:00 pm - 1:00 pm ET 

Overview

Elevate your skills and expertise in Benzodiazepine Tapering with our webinar series, based on Joint Clinical Practice Guideline on Benzodiazepine Tapering. Participants will learn how to determine when the risks of continued Benzodiazepine prescribing outweigh the benefits for a given patient, and how to safely taper the medication when indicated in various settings. 

***This activity is eligible for CE Credits. 

Webinar Series Topics

  • Considerations for Benzodiazepine Tapering  
  •  Benzodiazepine Tapering for Older Adults 
  • Considerations for Tapering Benzodiazepines in Primary Care
  • Addressing Benzodiazepine Tapering Challenges 

This webinar series addresses the following ACGME Competencies: Patient Care, Medical Knowledge, Practice-Based Learning, and Improvement.  

Learning Objectives

Upon completion, learners will be able to:

  1. Apply key clinical takeaways and strategies for safely tapering benzodiazepines as outlined in the Joint Clinical Practice Guideline on Benzodiazepine Tapering.
  2. Recognize the importance of conducting risk-benefit assessments to inform tapering strategies, and close monitoring and adjustments based on a patient’s response during taper. 
  3. Understand the unique challenges and risks associated with tapering benzodiazepines in older adults. 
  4. Implement practical, evidence-based strategies for tapering benzodiazepines in primary care settings. 
  5. Apply evidence-based strategies to manage withdrawal symptoms and mitigate risks associated with high-severity benzodiazepine tapers.

Acknowledgment

The development of this Guideline was generously funded by grant U01FD007804 from the US Food and Drug Administration, the US Department of Health and Human Services. The contents are those of the authors and do not necessarily represent the official views of nor an endorsement by the FDA and Department of Health and Human Services or the US Government. The funders had no decision-making role in designing and conducting the systematic reviews, data collection, analysis, and interpretation of the data or approval privilege on the recommendations. As requested, FDA officers provided nonbinding feedback and technical support to the guideline panel and methodological team. This article was peer-reviewed before publication. These guidelines are intended to help inform clinical decision-making by prescribers and patients. They are not intended to be used for the purposes of restricting, limiting, delaying, or denying coverage for or access to a prescription issued for a legitimate medical purpose by an individual practitioner acting in the usual course of professional practice. 
 

Registration Rates

ASAM Learner TypeRate
ASAM Member$0
Non-Member$0
Associate Member$0
Resident Member*$0
Student Member*$0

*Residents, Fellows-in-training, Interns, and Students must join ASAM to receive a discounted registration rate. Click here to become an ASAM member. National and Chapter membership dues apply. There is no charge for Students to become a Member, but verification of student status is required.

Membership Question?  Call ASAM at 1.301.656.3920, email us, or view the ASAM website for more information.

Refunds & Cancellations

All ASAM e-Learning Center refund requests must be made in writing to Education@ASAM.org within 90 days of purchase. Those requesting refunds for courses that are in progress will receive partial refunds or e-Learning Center credit. Automatic full refunds will be made for any course with a live-course component that has been cancelled.

Open Registration: 2/24/25 – 5/26/25

Close Access Date: 4/8/28

Instructions

  1. Click on the Contents tab to begin this activity. 
  2. Click Complete Post Test to answer multiple choice questions. Participants will have 10 attempts to pass and must answer 2 out of 3 questions correctly.
  3. Click Complete Evaluation to provide valuable activity feedback. Scroll down on all questions as there may be answer options that expand past the size of the window. 
  4. Click the button Claim Medical Credits in the box titled Claim Credits & Certificate. Choose the type of credit and click submit. Click the button View/Print Certificate to save or print your certificate. You can view/print your certificate at any time by visiting the ASAM e-Learning Center, clicking Dashboard, and clicking Transcript/Achievements.


    Need Assistance?

    For assistance logging in, accessing activities, claiming credit, or for other questions or concerns, please check the FAQ page or e-mail Education@ASAM.org

    ASAM is proud to offer eSSENTIAL Accessibility to ensure our website is accessible and functional for all our learners while providing free assistive technology for people with the widest possible range of abilities.

    Amy M. VandenBerg

    PharmD, BCPP, FAAPP

    Dr. VandenBerg is a Clinical Associate Professor at the University of Michigan (U of M) College of Pharmacy, PGY2 Psychiatric Pharmacy Residency Program Director and Clinical Pharmacy Specialist in Psychiatry & Neurology at U of M Health. She earned her PharmD from the U of M College of Pharmacy and completed her PGY1 and PGY2 Psychiatric Pharmacy Residencies at the Medical University of South Carolina where she practiced until 2016. A Board-Certified Psychiatric Pharmacist since 2002, Dr. VandenBerg has extensive experience in psychopharmacology working with diverse patient populations across inpatient and ambulatory care settings, using medications to manage substance use, psychiatric and neurologic disorders. Dr. VandenBerg returned to U of M Health in 2016 as a Clinical Pharmacy Specialist and transitioned to Clinical Associate Professor at the U of M College of Pharmacy in 2020. Her inpatient practice areas at U of M include general adult neurology, adult psychiatry and consult-liaison psychiatry, addictions consult, and psychiatric emergency services. Dr. VandenBerg provides broad psychopharmacology education for pharmacy trainees and U of M Psychiatry Residency and Fellowship programs. In addition to her roles at U of M, Dr. VandenBerg serves as a content expert for Wolters-Kluwer (Lexi-Comp) and Assistant Editor for Pharmacotherapy: A Pathophysiologic Approach, 13th ed (Psychiatry and Neurology chapters)

    No relevant financial disclosures

    Chinyere Ogbonna

    MD, MPH

    Chinyere Ogbonna, MD, MPH received her medical degree from Temple University School of Medicine. She extended her medical school training in order to complete a Masters in Community Health Education from Temple University School of Public Health. She completed a combined family medicine and psychiatry residency at the University of Cincinnati/ The Christ Hospital in Cincinnati, OH. She continued her training with a fellowship in Addiction Medicine at Stanford Hospital & Clinics.

    Dr. Ogbonna is board certified in Family Medicine, Psychiatry, and Addiction Medicine. Dr. Ogbonna is an active speaker on screening, brief intervention, and referral to treatment (SBIRT), with a specific focus on prevention and early intervention among adolescents and young adults. Her clinical focus also includes perinatal addiction, dual diagnoses, chronic pain, and increasing the integration of medicine and psychiatry in primary care.

    Dr. Ogbonna currently is the Medical Director of Addiction Medicine & Recovery Services (AMRS) at Kaiser Permanente San Jose and Adjunct Faculty at Stanford Health. She continues to teach residents and fellows and collaborates with other medical providers to help improve patient access to addiction services.

    No relevant financial disclosures

    Key:

    Complete
    Failed
    Available
    Locked
    Attend Virtual Session - Monday, May, 19 ,2025
    05/19/2025 at 12:00 PM (EDT)  |  60 minutes
    05/19/2025 at 12:00 PM (EDT)  |  60 minutes Learners may join 15 minutes prior to start time. Audio is available via computer or mobile device speakers/headphones.
    Complete Post Test
    0 Question  |  10 attempts  |  2/0 points to pass
    0 Question  |  10 attempts  |  2/0 points to pass This post-test has 3 questions and requires 2 out of 3 questions to pass the test.
    Complete Evaluation
    14 Questions
    14 Questions Scroll down on evaluation, there may be questions that expand past the size of the window.
    Complete Presenter Evaluation
    4 Questions
    Claim Credit & Certificate
    Up to 1.50 medical credits available  |  Certificate available
    Up to 1.50 medical credits available  |  Certificate available Attendees should claim only the credit commensurate with the extent of their participation in the activity.
    ;